SAR442085
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $93,995 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $93,995 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | SANOFI US SERVICES INC. | $93,995 | 0 |
Top Doctors Receiving Payments for SAR442085
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $93,995 | 6 |
Manufacturing Companies
- SANOFI US SERVICES INC. $93,995
Product Information
- Type Drug
- Total Payments $93,995
- Total Doctors 0
- Transactions 6
About SAR442085
SAR442085 is a drug associated with $93,995 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2019 to 2019. In 2019, $93,995 was paid across 6 transactions to 0 doctors.
The most common payment nature for SAR442085 is "Unspecified" ($93,995, 100.0% of total).
SAR442085 is associated with 1 research study, including "An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)" ($93,995).